CARLSBAD, Calif., May 23, 2011 /PRNewswire/ — Isis
Pharmaceuticals, Inc. (Nasdaq:
ISIS), the leader in antisense therapeutics, today announced
that management will present a general corporate update in
conjunction with its 2011 Annual Meeting of Stockholders and Open
House on Thursday, June 16 at 2:15 p.m. Pacific Time in Carlsbad,
CA. The agenda for the meeting is as follows:2:00 p.m.
– 2:15 p.m. Annual Meeting of Stockholders (only for
stockholders of record as of April 20, 2011)2:15 p.m. – 3:00
p.m. Corporate Presentation – Stanley T. Crooke, Isis
Chairman and Chief Executive Officer3:00 p.m. – 5:00 p.m.
Poster PresentationA live audio webcast of the presentation will be
available on the “Investors & Media” section of the Company’s
Web site, www.isispharm.com. A
replay of the presentation will be available on the Isis Web site
within 48 hours and will be archived for a limited time.
ABOUT ISIS PHARMACEUTICALS, INC.Isis is exploiting its
expertise in RNA to discover and develop novel drugs for its
product pipeline and for its partners. The Company has
successfully commercialized the world’s first antisense drug and
has 24 drugs in development. Isis’ drug development programs
are focused on treating cardiovascular, metabolic, and severe
neurodegenerative diseases and cancer. Isis’ partners are
developing antisense drugs invented by Isis to treat a wide variety
of diseases. Isis and Alnylam Pharmaceuticals are joint
owners of Regulus Therapeutics Inc., a company focused on the
discovery, development and commercialization of microRNA
therapeutics. Isis also has made significant innovations
beyond human therapeutics resulting in products that other
companies, including Abbott, are commercializing. As an
innovator in RNA-based drug discovery and development, Is
‘/>”/>
SOURCE
